Cargando…

Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy

Expression of androgen receptor (AR) splice variant 7 (AR-V7) has been identified as the mechanism associated with the development of castration-resistant prostate cancer (CRPC). However, a potential link between AR-V7 expression and resistance to taxanes, such as docetaxel or cabazitaxel, has not b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimizu, Yasuomi, Tamada, Satoshi, Kato, Minoru, Hirayama, Yukiyoshi, Takeyama, Yuji, Iguchi, Taro, Sadar, Marianne D., Nakatani, Tatsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262607/ https://www.ncbi.nlm.nih.gov/pubmed/30453546 http://dx.doi.org/10.3390/jcm7110444

Ejemplares similares

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
por: Iguchi, Taro, et al.
Publicado: (2019)

Steroid sulfatase promotes invasion through epithelial-mesenchymal transition and predicts the progression of bladder cancer
por: Shimizu, Yasuomi, et al.
Publicado: (2018)

Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer
por: Tamada, Satoshi, et al.
Publicado: (2018)

Editorial Comment to Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy
por: Hirayama, Yukiyoshi, et al.
Publicado: (2021)

Editorial Comment from Dr Hirayama and Dr Iguchi to Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
por: Hirayama, Yukiyoshi, et al.
Publicado: (2021)

A Case of Metastatic Urachal Carcinoma Treated With FOLFIRI (irinotecan and 5-Fluorouracil/leucovorin) Plus Bevacizumab
por: Kanamaru, Tomohiro, et al.
Publicado: (2014)

Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
por: Imamura, Yusuke, et al.
Publicado: (2016)

Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer
por: Hirayama, Yukiyoshi, et al.
Publicado: (2020)

Transarterial chemoembolization of liver metastasis from renal cell carcinoma
por: Matsuda, Hiroto, et al.
Publicado: (2018)

The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria
por: Tamada, Satoshi, et al.
Publicado: (2018)

Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of rapamycin inhibitors
por: Tamada, Satoshi, et al.
Publicado: (2018)

Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants
por: Banuelos, Carmen A., et al.
Publicado: (2020)

Treatment outcomes of ureteral stenting for malignant extrinsic ureteral obstruction: a comparison between polymeric and metallic stents
por: Asakawa, Jumpei, et al.
Publicado: (2018)

18-Fluoride-labeled sodium fluoride positron emission tomography is effective for assessing the therapeutic effect of Radium 223; a case report
por: Hamada, Kousuke, et al.
Publicado: (2018)

Taxane-based Chemotherapy Induced Androgen Receptor Splice Variant 7 in Patients with Castration-Resistant Prostate Cancer: A Tissue-based Analysis
por: Shim, Myungsun, et al.
Publicado: (2019)

A Case of Pulmonary Pleomorphic Carcinoma With Renal Metastasis()
por: Shimizu, Yasuomi, et al.
Publicado: (2014)

Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer
por: Myung, Jae-Kyung, et al.
Publicado: (2017)

Comparative effectiveness of radical prostatectomy and curative radiotherapy in localized prostate cancer: long-term follow-up
por: Tamada, Satoshi, et al.
Publicado: (2017)

Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer
por: Shan, Xiaochuan, et al.
Publicado: (2015)

Replication study: androgen receptor splice variants determine taxane sensitivity in prostate cancer
por: Shan, Xiaochuan, et al.
Publicado: (2018)

Carbonic anhydrase 2 is a novel invasion‐associated factor in urinary bladder cancers
por: Tachibana, Hirokazu, et al.
Publicado: (2017)

Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer
por: Tinzl, Martina, et al.
Publicado: (2013)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Kamikihito improves cancer-related fatigue by restoring balance between the sympathetic and parasympathetic nervous systems
por: Tamada, Satoshi, et al.
Publicado: (2018)

Successful case of olaparib treatment for castration-resistant prostate cancer with multiple DNA repair gene mutations: Use of comprehensive genome profiling for treatment-refractory cases
por: Hirayama, Yukiyoshi, et al.
Publicado: (2022)

Impact of taxanes on androgen receptor signaling
por: Bai, Shanshan, et al.
Publicado: (2019)

Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer
por: Tinzl, Martina, et al.
Publicado: (2018)

Anti‐PD‐L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma
por: Hirayama, Yukiyoshi, et al.
Publicado: (2016)

Pin1 inhibition improves the efficacy of ralaniten compounds that bind to the N-terminal domain of androgen receptor
por: Leung, Jacky K., et al.
Publicado: (2021)

ERG induces taxane resistance in castration-resistant prostate cancer
por: Galletti, Giuseppe, et al.
Publicado: (2014)

Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
por: Sekine, Yoshitaka, et al.
Publicado: (2021)

Non-Genomic Actions of the Androgen Receptor in Prostate Cancer
por: Leung, Jacky K., et al.
Publicado: (2017)

Heat shock protein 70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells
por: Kita, Kazuaki, et al.
Publicado: (2017)

Association of MnSOD AA Genotype with the Progression of Prostate Cancer
por: Iguchi, Taro, et al.
Publicado: (2015)

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
por: Bumbaca, Brandon, et al.
Publicado: (2018)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
por: Jiménez, Natalia, et al.
Publicado: (2020)

Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens
por: Ito, Yusuke, et al.
Publicado: (2018)

Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming treatment resistance in immunologically cold urothelial carcinoma
por: Yamamoto, Shoma, et al.
Publicado: (2023)

Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer
por: Naiki-Ito, Aya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e8qfa1icqe0nb8g4uhlt7lm8o5